Scientists find cause of reduced drug sensitivity in HER2-positive breast cancer
In the presence of the HER2 inhibitor lapatinib, the tumor suppressor molecule FOXO changes role and desensitizes HER2+ breast cancer cells to the drug, leading to relapse.